Cyclical vomiting syndrome. Nausea and vomiting
Conditions
Interventions
Intervention 1: Intervention group: In one group we will start Amitriptyline for patients with the dosage of 1 mg/kg daily. Patients won't be aware of their drugs. Intervention 2: Control group: In th
Treatment - Drugs
Intervention group: In one group we will start Amitriptyline for patients with the dosage of 1 mg/kg daily. Patients won't be aware of their drugs.
Control group: In the other group we will start Cyptoheptadine for patients with the dosage of 0.1-0.2 mg/kg BID.
Sponsors
Vice Chancellor of Research of Isfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
3 Years to 15 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Children 3-15 years old with diagnosis of cyclic vomiting syndrome (based on Rome III criteria: 1 Stereotypical episodes of vomiting regarding onset (acute) and duration (less than 1 week); 2) Three or more discrete episodes in the prior year; and 3) Absence of nausea and vomiting between episodes and absence of metabolic, gastrointestinal, central nervous system structural or biochemical disorders); Normal Neurological and Developmental examination Exclusion criteria: Known metabolic disease; Obstructive disease of gastrointestinal or urinary system; Patients who don't give consent to participate in the study or want to leave the study anytime.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of cyclic vomiting syndrome. Timepoint: From the recruitment date to 6 months after starting the medication. Patients are followed every two weeks after starting the medication. Method of measurement: questionnaire (evaluating number of attacks, duration of attacks, number of hospitalization). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShervin Badihian
Isfahan University of Medical Sciences, School of Medicine, Students' Research Center
Outcome results
None listed